| content | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Bitolterol
|
|
| Systematic (IUPAC) name | |
| [4-(1-Hydroxy-2-tert-butylamino-ethyl)- 2-(4-methylbenzoyl)oxy-phenyl] 4-methylbenzoate | |
| Identifiers | |
| CAS number | |
| ATC code | R03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C28H31NO5 |
| Mol. mass | 461.549 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Bitolterol mesylate (Tornalate) is a β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD.
Bitolterol has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.
Bitolterol was withdrawn from the market by Élan Pharmaceuticals in 2001.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||
